Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
As of September 18, 2026, PI Industries is exhibiting a bearish trend across daily, weekly, and monthly timeframes. The daily trend shows the closing price at ₹2366.8, below the 20-day Exponential Moving Average (EMA) of ₹2396.53 and the 50-day Simple Moving Average (SMA) of ₹2553.23. The monthly trend also indicates a bearish Supertrend direction, with the closing price below the 20-day EMA of ₹3048.75 and the 20-day SMA of ₹3229.28. The weekly trend similarly shows a bearish Supertrend direction, with the closing price below the 20-day EMA of ₹2644.06 and the 50-day SMA of ₹3007.14.
As of September 18, 2026, PI Industries has several identified levels. The nearest support levels are at ₹2353.5 (0.56% below the current price) and ₹2352.33 (0.61% below). The nearest resistance level is at ₹2387.67, which is 0.88% above the current price. Other identified resistance levels are at ₹2921.9, ₹3251.31, and ₹3532.33.
As of September 18, 2026, PI Industries has experienced varied returns across different periods. The one-year return is -36%, and the year-to-date return is -26%. Over the last six months, the return is -19%, and over the last three months, it is -17%. The one-month return is -6%, while the return over the last 10 days is -2%. The return over the last 5 days is 0%.
PI Industries has scheduled several meetings with analysts and institutional investors in early September 2026. On September 3, 2026, the company planned to meet with Vidrum Mehta from ASK Investment Managers, Abhijit Akella from Kotak Institutional Equities, Riju Dalui from Canara HSBC Life Insurance, and Priyansh Kothari from Fortitude Fund Management LLP. Further engagements were scheduled for September 9, 2026, with a representative from Aberdeen, and on September 10, 2026, with an equity fund manager from Kotak Mutual Fund. The company has stated that no unpublished price-sensitive information is intended to be shared during these meetings.
As of 18 Sept 2026, 03:30 pm
Recent drawdown or price variability is materially high and may lead to larger short-term outcomes.
Primary driver: Price remains materially below a previous peak
Trading activity was substantially higher than usual and the price closed lower.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
The session opened materially above the previous close, indicating a sharp repricing at the open.
The move may reflect new information; subsequent price follow-through is worth monitoring.
Trading activity was substantially higher than usual and the price closed lower.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | ₹1,702.30 crore | ₹1,565.20 crore | ₹1,375.70 crore | ₹1,872.30 crore | PEAK₹1,900.50 crore |
| Finance Costs | PEAK₹7.90 crore | ₹3.70 crore | ₹6.20 crore | ₹2.60 crore | ₹3.90 crore |
| Profit Before Tax | ₹319.90 crore | ₹300.10 crore | ₹362.50 crore | PEAK₹523.20 crore | ₹504.60 crore |
| Tax Expense | ₹77.60 crore | ₹100.30 crore | ₹51.60 crore | PEAK₹116 crore | ₹107.40 crore |
| Profit Loss For Period | ₹244.20 crore | ₹200.20 crore | ₹311.30 crore | PEAK₹409.30 crore | ₹400 crore |
| Segment Revenue From Operations | ₹1,702.30 crore | ₹1,565.20 crore | ₹1,375.70 crore | ₹1,872.30 crore | PEAK₹1,900.50 crore |
PI Industries operates through its Agri Sciences and Health Sciences segments. Aggregate segment revenue matched total revenue at ₹1,702.30 crore, and total segment profit before tax was ₹321.80 crore. That segment-level profit was ₹1.90 crore higher than the consolidated PBT of ₹319.90 crore, reflecting the net effect of unallocated items.
The quarter was defined by a significant year-on-year contraction in both revenue and profit. The drop in profit was amplified by a sharp rise in finance costs, while revenue recovered somewhat from the immediate prior quarter. Total segment profit remained close to the consolidated pre‑tax result.
Exchange disclosures and regulatory announcements for PI Industries.
PI Industries Limited scheduled a one-on-one analyst meeting with UTI Mutual Fund's CIO Ajay Tyagi on September 23, 2026, at 3:30 PM in Mumbai, as disclosed on September 18, 2026.
PI Industries Limited will hold a one-on-one meeting with UTI Mutual Fund in Mumbai on September 23, 2026, as disclosed under Regulation 30(6) of SEBI (LODR) Regulations, 2015. The company confirmed that no unpublished price sensitive information is proposed to be shared during the interaction. The schedule is subject to change due to exigencies on either side.
PI Industries Limited announced on September 3, 2026, a schedule of meetings with institutional investors and analysts. The company will meet Vidrum Mehta from ASK Investment Managers at 10:00 AM, Abhijit Akella from Kotak Institutional Equities at 12:00 PM, and Riju Dalui from Canara HSBC Life Insurance at 4:30 PM.
PI Industries Limited will interact with analysts and investors from ASK Investment Managers, Kotak Institutional Equities, and Canara HSBC Life Insurance on September 3, 2026, with no unpublished price sensitive information proposed to be shared.
PI Industries will interact with analysts and investors on September 3, 2026 (Fortitude Fund Management), September 9, 2026 (Aberdeen), and September 10, 2026 (Kotak Mutual Fund), with no unpublished price-sensitive information intended to be shared.
PI Industries Limited announced scheduled meetings with institutional investors and analysts, beginning with Fortitude Fund Management LLP analyst Priyansh Kothari on September 3, 2026, at 11:00 AM. Subsequent engagements include Aberdeen representative Tanvi Mashelkar on September 9, 2026, at 9:00 AM, and Kotak Mutual Fund equity fund manager Arjun Khanna on September 10, 2026, at 2:30 PM.
PI Industries Limited has informed the Exchange about Schedule of meet with Aberdeen |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
PI Industries Limited has informed the Exchange about Schedule of meet with Kotak Mutual Fund |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
Recent market and company developments associated with PI Industries.
FIIs sold ₹931 crore of Indian equities on Friday, while DIIs bought ₹1,968 crore as the Sensex and Nifty fell for a fifth straight week.
The Sensex slipped 121 points to 74,782, while the Nifty fell 80 points to 23,398. The Nifty Bank ended 135 points higher at 56,607, while the Nifty Midcap index declined 160 points to 62,197.
Kumiai Chemicals, a key client, has cut its profit guidance for its fiscal year, which ends on October 31, 2026. The full year operating profit guidance has been cut to 2,700 million yen compared to its previous guidance of 7,200 million yen.
Nifty has experienced a decline for four straight weeks, breaking through the crucial 24,000 support level. Experts recommend adopting a market-neutral approach to capitalize on expected volatility. Among the stocks to watch are APL Apollo Tubes and One 97 Communications, which may offer promising returns. The Bank Nifty indicates upward trends, encouraging investors to buy on dips around 56,400. Additionally, Hindustan Oil Exploration Company and Engineers India present attractive opportunities...
Vaishali Parekh recommends three stocks to buy today — Titagarh Rail Systems, Edelweiss Financial Services, and PI Industries
PI Industries aims to offset earnings declines and global agrochemical headwinds by shifting from contract manufacturing to proprietary R&D and non-agri diversification.
Sensex, Nifty, Share Prices Live: Indian equities remained subdued despite stronger Asian markets, with firm crude prices and geopolitical risks keeping investors cautious. Domestic inflation, MSCI’s latest reshuffle and expectations around RBI policy are also likely to influence trading sentiment during Thursday’s session.
Sensex Today | Stock Market LIVE Updates: Today is the Sensex weekly options expiry session. The Nifty though, finds itself stuck below the 24,500 mark, although a late charge from the Nifty Bank on Wednesday ensured that the index managed to close above 24,400.
Comprehensive Section Breakdown for PI Industries
Strategic Vision: Integrated agrisciences and life sciences solutions provider.
• Integrated business model across agri-value chain
• End-to-end CRDMO solutions for health sciences
PI Industries reported a challenging first quarter for the fiscal year ending June 2026. Consolidated revenue from operations declined by over 10% year-on-year, while net profit fell nearly 39%. Sequentially, revenue and profit improved from the prior quarter. The year-on-year weakness was compounded by a sharp increase in finance costs, which widened the gap between revenue and profit. Total segment profit before tax was ₹321.80 crore, marginally above the consolidated profit before tax of ₹319.90 crore.
Revenue from operations for the quarter ended 30 June 2026 was ₹1,702.30 crore, a decline of 10.43% compared to ₹1,900.50 crore in the same quarter last year. On a sequential basis, revenue rose by 8.76% from ₹1,565.20 crore in Q4 FY26.
The top line has been uneven across recent quarters. After a contraction in Q4 FY26, the first quarter showed a partial recovery. The year-on-year drop remains the dominant feature, while the sequential uptick provides a near-term counterpoint.
Profit before tax (PBT) for the quarter stood at ₹319.90 crore, down 36.6% from ₹504.60 crore in the year-ago quarter. Sequentially, PBT improved by 6.6% from ₹300.10 crore. Net profit (profit for the period) fell 38.95% year-on-year to ₹244.20 crore from ₹400 crore, but it rose 21.98% from ₹200.20 crore in the previous quarter.
Finance costs rose sharply. They more than doubled year-on-year, climbing from ₹3.90 crore to ₹7.90 crore. Compared with ₹3.70 crore in Q4 FY26, finance costs increased by 113.51%. This escalation was a key factor driving the larger year-on-year decline in profit relative to revenue.
Tax expense decreased to ₹77.60 crore from ₹100.30 crore in the prior quarter, a reduction of 22.63%. The effective tax rate moderated, allowing net profit to grow faster than pre-tax profit on a sequential basis (22% vs. 6.6%).
Other comprehensive income (OCI) swung from a loss of ₹40.60 crore in Q4 FY26 to a gain of ₹32 crore in the current quarter, a movement of ₹72.6 crore. This swing highlights volatility in non-operating items that does not directly affect net profit.
Other income for the quarter was ₹64.10 crore. On the cost side, material consumption totalled ₹681.90 crore, employee benefit expenses were ₹260.80 crore, and depreciation and amortisation amounted to ₹103.70 crore.
PI Industries reported a challenging first quarter, with consolidated revenues falling 10.4% year-on-year to Rs 17,023 million and net profit declining 38.9% to Rs 2,442 million. The agro chemicals segment remained profitable, contributing Rs 3,835 million in pre-tax profit, while the pharma segment continued to be a drag, posting a pre-tax loss of Rs 816 million. Management noted no exceptional items in the quarter, contrasting with the prior quarter's loss, and reaffirmed confidence in the long-term prospects of its PI Health Sciences subsidiary despite a prior impairment. Strategically, the board approved the incorporation of a wholly owned Section 8 company, 'PI Foundation', dedicated to corporate social responsibility activities.
Category: Supply Chain
Focuses on bringing agricultural solutions and knowledge to farmers, integrating every step in the agri-value chain.
Key Products & Services: Brofreya • Eketsu
Category: B2B Services
Offers end-to-end Contract Research, Development, and Manufacturing Organization (CRDMO) solutions for the health sciences sector.
Core Thesis: The company integrates various steps across the agri-value chain and provides end-to-end contract research and manufacturing solutions for the health sciences sector.
• Agri Sciences Integration: Integrates discovery, development, custom synthesis, manufacturing, and crop solutions across the agri-value chain. • Health Sciences CRDMO: Provides seamless, single-ownership contract research, development, and manufacturing services for the pharmaceutical industry.